<DOC>
	<DOCNO>NCT01362400</DOCNO>
	<brief_summary>The purpose study compare impact IPI-504 combination docetaxel placebo combination docetaxel life expectancy patient Non Small Cell Lung cancer ( NSCLC ) . Docetaxel approve chemotherapy NSCLC . An additional goal study determine effect IPI-504 , combination docetaxel , verse placebo , combination docetaxel , growth cancer</brief_summary>
	<brief_title>A Double-blind Study Evaluating IPI-504 Docetaxel Patients With Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>This Phase 2 , double-blind , randomize , placebo-controlled study patient previously treat , locally advanced metastatic Stage IIIb IV NSCLC design compare IPI-504 plus docetaxel versus placebo plus docetaxel . All patient least 15 pack year smoke history . Tumor sample assess central pathology reviewer confirm pathology document baseline ; review need occur advance randomization .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Patients must ≥18 year age Voluntarily sign informed consent Confirmed NSCLC Stage IIIB IV disease . At least ≥15 pack year smoke history must active smoker within 20 year diagnosis . Must archival NSCLC tissue available provide analysis lesion accessible biopsy Must experience disease progression receive least 1 prior platinumcontaining chemotherapy regimen . Must receive 2 prior chemotherapy regimens Measurable disease RECIST 1.1 criterion . ECOG performance status 0 1 ( Refer scale Appendix 1 ) . Women childbearing potential ( WCBP ) , sexually active male patient , partner patient must agree use adequate method birth control . Prior docetaxel , IPI504 Hsp90 inhibitor treatment Known hypersensitivity drug formulate polysorbate80 . Not recovered toxicity relate prior treatment Use medication food clinically relevant CYP3A inhibitor inducer Inadequate hematologic function Inadequate hepatic function Inadequate renal function Symptomatic keratitis keratoconjunctivitis . Uncontrolled systemic fungal , bacterial , viral infection Patients clinically active brain metastasis Patients clinically stable brain metastasis ( previously treat untreated ) eligible . Sinus bradycardia ( rest heart rate &lt; 50 bpm ) . Significant cardiac disease Previous current malignancy sit within last 2 year Prior hepatic resection hepaticdirected therapy Known HIVpositive patient receive combination antiretroviral therapy . Women pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>LUNG NEOPLASMS</keyword>
	<keyword>LARGE CELL CARCINOMA</keyword>
	<keyword>SQUAMOUS CELL CARCINOMA</keyword>
</DOC>